ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
rdf:type |
rdfs:Resource |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
rdf:type |
owl:Thing |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
rdf:type |
ripe:IntegrityAssessmentHypothesisIntegrity assessment hypothesis |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
rdf:type |
tido:Hypothesis |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
prov:wasAttributedTo |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI 1.0.0 |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
prov:wasAttributedTo |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
prov:wasGeneratedBy |
ripekg:evaluation/RIPEA1195AD8EF5C09D44 |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA1195AD8EF5C09D44 |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
ripe:resultOutcome |
yes |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
tido:answers |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.01.3. Do other studies by the research team highlight causes for concern? |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
tido:answers |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.0research-team-related concerns |
ripekg:retraction-notice/35137Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |
ripekg:retraction-notice/60864Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized platform clinical trial |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA1195AD8EF5C09D44-inspectai-1-3 |